Block Listing 6 Monthly Return

RNS Number : 6269A

Shield Therapeutics PLC

30 September 2020

 

Shield Therapeutics plc

("Shield" or the "Group")

Block Listing 6 Monthly Return

Date: 30 September 2020

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		S hield Therapeutics Retention Share Plan
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		54,219
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		54,219

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		388,079
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		388,079

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		171,883
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		171,883

Name of applicant:		SHIELD THERAPEUTICS PLC
Name of scheme:		Shield Therapeutics Retention and Performance Share Plan
Period of return:	From:	06 March 2020	To:	30 September 2020
Balance of unallotted securities under scheme(s) from previous return:		1,885,819
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		NIL
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		NIL
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		1,885,819

Name of contact:	Lucy Huntington-Bailey
Telephone number of contact:	[phone]

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Tim Watts, Chief Executive Officer	[phone]
Lucy Huntington-Bailey, General Counsel and Company Secretary	[phone]
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

BLREAANEDFXEEFA